Business Wire

Brussels Signal: New Media Outlet Promises to Shake Up EU Coverage

31.5.2023 11:03:00 EEST | Business Wire | Press release

Share

Digital publisher Remedia Europe is preparing a groundbreaking news outlet, Brussels Signal , that promises to provide fresh and candid coverage of EU affairs and the issues that matter most to the citizens of Europe.

Brussels Signal will deliver rigorous reporting and analysis of the European Union. The news outlet aims to shake up the status quo by providing insightful and informed journalism that challenges prevailing ideas and policies, demands genuine accountability from decision-makers, and counters the marginalisation of dissenting voices on the issues facing Europe today.

An early version of Brussels Signal opens May 31 with an invitation to join a live event with the new editors. Other features of the news outlet – including video content and newsletters – will roll out in the coming weeks, with events coming this autumn at the Brussels Signal’s purpose-built studio in the heart of the European Quarter of Brussels.

The new media brand emerges at a time when the EU faces internal differences among Member States that are testing the work of the EU and questioning the shape and substance that European unity will take. External challenges including the war in Ukraine, energy security, migration, and trends in geopolitics are set to try the EU as a global player, and upcoming elections present opportunities for it to demonstrate its ambitions.

Meanwhile, the news industry is seeing consolidation, which means not more voices but fewer. Today’s European citizens demand greater freedom in news media, sources that raise tough questions and encourage unfettered debate; media pluralism is an essential part of this.

“We’re thrilled to introduce Brussels Signal,” said Michael Mosbacher, who played leading roles in the launch of Standpoint and The Critic in the UK and serves as Editor-in-Chief of the new media outlet. “Our team of talented journalists is dedicated to delivering accurate, timely, and insightful coverage of the most important issues affecting people throughout Europe. Our objective is to critically examine the news of the day and present a distinctive alternative viewpoint, offering a captivating source of content that engages and enlightens our audience.”

Justin Stares, a Brussels-based correspondent whose bylines have appeared in The Telegraph, Sunday Telegraph, New York Times, The Guardian, Observer, and other titles, will serve as senior editor for news. Justin is also founder of The Maritime Watch, an EU policy news service, and author of several books, most recently This is Belgium, a political, economic and social analysis of the country that hosts the EU institutions.

The site will feature regular commentary and analysis from well-known and emerging voices, including Douglas Murray, Anne-Elisabeth Moutet, Dominic Green, Kapil Komireddi, Alessandra Bocchi, William Nattrass, Ralph Schoellhammer and Felipe Fernandez-Armesto. Authored newsletters with a regional and thematic focus will highlight developments underreported in Brussels. Plus, engaging video content, including interviews with opinion leaders and podcasts.

“The EU and its Member States remain indispensable in this environment fraught with crisis and conflict, and there’s no question that European institutions and the people of Europe would benefit from a distinctive source of news and insights,” said Patrick Egan, Remedia Europe CEO and publisher of Brussels Signal. “What you see now at Brussels Signal is just the beginning. We’re ramping up our products – newsletters, podcasts and more – in our endeavour to shake up the news media landscape.

“When we look at the current media landscape, we see an opportunity. Rather than sit on the sidelines, I decided to invest my time and money to pursue that opportunity and bring about the change we need. Now we have the seed capital to finally launch with confidence in our news brand and its prospects as a sustainable business, one that will constructively influence the conversation at the European level.”

ENDS

Brussels Signal (https://brusselssignal.eu/) provides rigorous reporting on the important issues affecting citizens across Europe. Challenging the status quo with a focus on delivering insightful coverage of the issues shaping the Europe of today and tomorrow, our seasoned editors and contributors offer a distinct perspective on the news.

For more information about Brussels Signal and to read its coverage, visit www.brusselssignal.eu.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For press inquiries
contact@brusselssignal.eu.

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release

PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release

Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release

Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye